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BRIEF RESEARCH REPORTSQuantity, particle size, and histologic composition of embolic debris
collected in a distal protection filter after carotid angioplasty and
stenting: Correlation with patient characteristics, timing of carotid
artery stenting, and procedural detailsJorinde H. H. van Laanen, MD,a Joke M. Hendriks, MD, PhD,a Hence J. M. Verhagen, MD, PhD,a and
Heleen M. M. van Beusekom, PhD, FESC,b Rotterdam, The NetherlandsTABLE 1. Patient (n ¼ 55) and lesion (n ¼ 59) characteristics
Patients, n (%)
Age, y Mean, 67.2 (range, 47-89)
Male sex 36 (66)
Hypertension 43 (78)
Hypercholesterolemia 41 (75)
Diabetes 9 (16)
Cardiac disease 13 (24)
Chronic renal insufficiency 9 (16)
Smoking history 39 (71)
Lesions, n (%)
Asymptomatic 5 (8.5)
Symptomatic 54 (91.5)
Amaurosis fugax 8 (14)
Retinal infarction 1 (2)
Transient ischemic attack 28 (48)
Stroke 17 (29)
Onset of symptoms before CAS
0-28 d 35 (59)
>28 d 24 (41)
Contralateral occlusion 10 (17)
Percent stenosisThe occurrence of distal embolization during carotid artery
stenting (CAS) is a major complication. Determining the
preoperative risk of embolization may lead to improved pa-
tient selection and outcome of CAS. This study examined
the quantity, particle size, and histologic composition of
embolic debris collected in a distal protection filter and its
possible correlation with patient characteristics, timing of
CAS, and procedural details.
CLINICAL SUMMARY
Subjects
Patients who underwent a CAS procedure during
a 17-month period in which a SPIDER Embolic Protection
Device (EPD) (ev3 Endovascular Inc, Plymouth, Minn) was
used were included. Patient demographics, cardiovascular
risk factors, neurologic symptoms, and time interval be-
tween symptoms and CAS were retrospectively recorded.
Procedure
CAS was performed according to the standardized proto-
col in our center as described previously.1 This protocol also
dictates the antiplatelet regimen.FIGURE 1. Macroscopic images of EPD containing embolic
50%-69% 4 (7)
70%-99% 55 (93)
CAS, Carotid artery stenting.
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Debris was photographed before (Figure 1, A) and after
(Figure 1,B) removal from the EPD. Clemex image analysis
software (Clemex Technologies Inc, Longueuil, Canada)
was used to analyze the number and size of the particles.
Consecutive series of paraffin sectionswere stainedwith he-
matoxylin–eosin as a routine stain, resorcin-fuchsin formaterial (A, arrow) and debris as retrieved from EPD (B).
ery c August 2013
TABLE 2. Patient and procedural characteristics of 44 cases with embolic particles in the Embolic Protection Device and number and size of
particles
N ¼ (%) No. of particles, median (min-max) P value
Length of particles, median
(min-max) P value
Age (y) mean, 67.6 (47-89)
Less than or equal to mean 22 (50) 8 (1-29) .51 670 (60-6045) .09
Greater than mean 22 (50) 9 (1-47) 609 (79-9423)
Sex
Male 29 (65.9) 10 (1-47) .98 615 (60-9423) .31
Female 15 (34.1) 7 (1-29) 728 (79-6771)
Hypertension
Yes 38 (86.4) 9.5 (1-31) .37 684 (60-9423) .013
No 6 (13.6) 3.5 (1-47) 474 (129-3681)
Hypercholesterolemia
Yes 30 (68.2) 10 (1-24) .31 653 (60-6771) .43
No 14 (31.8) 5.5 (1-47) 621 (79-9423)
Diabetes
Yes 9 (20.5) 13 (3-31) .5 782 (135-9423) .018
No 35 (79.5) 8 (1-47) 615 (60-6045)
Cardiac disease
Yes 10 (22.7) 9.5 (3-24) .83 707 (60-6771) .17
No 34 (77.3) 8.5 (1-47) 629 (79-9423)
Chronic renal insufficiency
Yes 9 (20.5) 8 (1-24) .77 706 (147-4676) .38
No 35 (79.5) 9 (1-47) 636 (60-9423)
Smoking history
Yes 31 (70.5) 7 (1-47) .029 643 (60-9423) .42
No 13 (29.5) 14 (4-29) 643 (79-6771)
Asymptomatic
Yes 3 (6.8) 3 (1-14) .23 546 (169-1728) .76
No 41 (93.2) 9 (1-47) 645 (60-9423)
Symptomatic
Amaurosis fugax 4 (9.1) 4 (1-21) .24 650 (213-4095) .22
Transient ischemic attack 23 (52.3) 8 (1-31) 669 (79-9423)
Stroke 14 (31.8) 11.5 (2-47) 606 (60-6771)
Onset of symptoms before CAS
0-28 d 28 (64) 10 (1-47) .048 653 (60-9423)
>28 d 16 (36) 4 (1-23) 615 (135-4676) .51
Duration CAS
<2 h 21 (48) 8 (1-31) .46 695 (60-9423) .25
2 h 23 (52) 10 (2-47) 603 (79-6045)
Predilation
Yes 40 (91) 8.5 (1-47) .87 630 (60-9423) .52
No 4 (9) 9 (1-19) 838 (125-4102)
Postdilation
Yes 41 (93) 9 (1-47) .89 633 (60-9423) .14
No 3 (7) 7 (5-13) 881 (160-4676)
Stent type
Acculink 30 (68) 8 (1-47) .60 599 (79-6045) .21
Protege 7 (16) 13 (3-31) 714 (60-9423)
Other 7 (16) 10 (4-21) 615 (135-4676)
CAS, Carotid artery stenting.
Brief Research Reportscollagen and elastin, and von Kossa for collagen and calcified
tissue to study the particles at different depths.Debriswas clas-
sified as thrombus (containing platelets, erythrocytes, and fi-
brin), atheroma (fibrous matrix, cholesterol clefts, and foam
cells), and calcified tissue on the basis of morphologic criteria.The Journal of Thoracic and CaStatistical Analysis
Data were analyzed using SPSS software (SPSS Statistics
17.0; SPSS Inc, Chicago, Ill). Continuous variables were ex-
pressed as median (minimum-maximum) in case normality
could not be assumed and comparedwith nonparametric tests.rdiovascular Surgery c Volume 146, Number 2 493
FIGURE 2. Histology of embolic debris contains both thrombus and atheromatous material characterized by the cholesterol clefts (A, arrows). Within the
debris, polymeric material (B, arrows) and calcific nodules (C, arrows) were observed. A and C, Hematoxylin–eosin. B, von Kossa.
Brief Research ReportsRESULTS
Patients and Procedures
Demographics of the 55 included patients and details of
the 59 treated stenotic lesions in these patients are presented
in Table 1.Histopathology
Macroscopic evaluation detected particles in 44 of the 59
collected filters (75%) (Figure 1). Table 2 represents patient
and procedural details of these cases and the number and
size of the detected particles. The EPD in patients who
smoked showed a significantly lower number of particles
compared with nonsmokers (7 vs 14, P ¼ .029). The num-
ber of particles was significantly higher when CAS was494 The Journal of Thoracic and Cardiovascular Surgperformed in the first 4 weeks after the qualifying neuro-
logic event (10 vs 4, P ¼ .048).
Qualitative assessment of histologic sections showed deter-
minable embolic debris in 36 (82%) of the processed filters.
Embolic particles consisted of atheromatous debris in 13 cases
(36%), thrombus in 16 cases (44%), and calcified tissue in 7
cases (19%) (Figure2).Atheromatousplaquesgeneratedasig-
nificantly higher number of particles (median 14, P ¼ .01).DISCUSSION
Despite the use of protection devices, cerebral embolization
has been shown by transcranial Doppler and diffusion-
weighted magnetic resonance imaging.2,3 Although most of
the clinical implications of detected microemboli remainery c August 2013
Brief Research Reportsundefined, associationwith deterioration in cognitive function
6 months after CAS has been reported.4 Currently, no protec-
tion device can completely prevent distal embolization. Fur-
thermore, dislodgement of embolic debris can occur during
guidewire manipulation and protection device positioning or
removal. Determining the risk factors for embolization could
lead to a better patient selection, improving outcomes ofCAS.
Unstable, echolucent atherosclerotic plaques have been
associated with increased embolic potential and increased
risk of stroke in CAS.5 This study confirms the increased
embolic potential, because we found a significantly higher
number of embolic particles when CAS was performed in
the first weeks after symptoms and a significantly higher
number of particles in atheromatous plaques.
Older age, hypertension, hypercholesterolemia, coronary
artery disease, symptomatic lesions, number of balloon
dilations, and stent diameter have unequivocally been asso-
ciated with increased embolic potential. In this study, we
found only smoking to be negatively correlated with the
number of dislodged particles during CAS. A possible ex-
planation for this finding is that plaque composition in
smokers differs from nonsmokers because of different etiol-
ogy, and these plaques could be more stable.
Because of the method of histologic processing and sec-
tion staining, not all filters containing embolic debrisFrom the Departments of Thoracic Surgerya and Anesthesiology and Intensive Care,b
Policlinico Tor Vergata University, Rome, Italy.
Disclosures: Authors have nothing to disclose with regard to commercial support.
The Awake Thoracic Surgery Research Group is listed in the Appendix.
Received for publication Dec 5, 2012; revisions received March 19, 2013; accepted
for publication March 25, 2013; available ahead of print April 22, 2013.
Address for reprints: Eugenio Pompeo, MD, Section of Medical and Surgical Lung
Diseases, Department of Biomedicine and Prevention, Tor Vergata University,
Via Montpellier 1, 00133 Rome, Italy (E-mail: pompeo@med.uniroma2.it).
J Thorac Cardiovasc Surg 2013;146:495-7
0022-5223/$36.00
Copyright  2013 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2013.03.038
The Journal of Thoracic and Caappeared in the qualitative analysis. In addition to the small
sample size, this is a limitation of this study.
CONCLUSIONS
The detailed analysis of embolic debris and the findings
that lesion characteristics and timing of intervention seem
to be the most important factors influencing distal emboli-
zation during CAS and contribute to further understanding
the mechanism of embolization and better patient
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outcome. Eur J Neurol. 2007;14:672-8.Is there any benefit in using awake anesthesia with thoracic epidural
in thoracoscopic talc pleurodesis?Eugenio Pompeo, MD,a and Mario Dauri, MD,b for the Awake Thoracic Surgery Research Group,
Rome, ItalySupplemental material is available online.
General anesthesia is commonly used for video-assisted
thoracic surgery (VATS) with talc pleurodesis, although
use of regional anesthesia in the awake patient mightimprove outcomes.1,2 The purpose of this randomized
study is to compare the hospital discharge of patients
undergoing VATS with talc pleurodesis using thoracic
epidural or general anesthesia.CLINICAL SUMMARY
Forty patients with malignant pleural effusion were
randomized to undergo VATS with talc pleurodesis by
awake anesthesia with thoracic epidural (awake group,
N ¼ 20) or general anesthesia and 1-lung ventilation
(control group, N ¼ 20) (ClinicalTrials.gov registration
No. NCT01469728). The study was approved by the Po-
liclinico Tor Vergata University ethical committee, and
written informed consent was obtained by the patients.
Eligibility criteria are summarized in Table E1.
In the awake group, the thoracic epidural catheter was in-
serted at the T4 level for continuous infusion of ropivacainerdiovascular Surgery c Volume 146, Number 2 495
